不同药物治疗变态反应性结膜炎的疗效分析被引量：1

Efficacy of Different Drug Treatment of Allergic Conjunctivitis

导出

摘要目的:探讨不同药物治疗变态反应性结膜炎的临床疗效。方法:回顾性分析2009年6月-2011年6月笔者所在医院收治的80例变态反应性结膜炎患者的临床资料。结果:用药后3d,两组显效率、总有效率比较差异有统计学意义(P<0.05);用药后7、14d和停药后7d,两组显效率、总有效率比较差异均无统计学意义(P>0.05)。结论:氮卓斯汀与奥洛他定汀的应用均安全有效,但在用药初期氮卓斯汀明显优于奥洛他定汀,作用更迅速,效果更明显。 Objective ：To investigate the clinical efficacy of different drug treatment of allergic conjunctivitis.Methods ：Retrospectively analysed the clinical data of 80 cases admitted to hospital from Jun 2009 to Jun 2011 in patients with allergic conjunctivitis.Results ：3 days after treatment between the two groups was significant efficiency and total efficiency of the significant difference （P〈0.05） ; 7, 14 days after treatment and withdrawal, the difference between the two groups were not statistically signifieant（P〉0.05）.Conclusion ：Azelastine and olopatadine of the applications are safe and effective. However, early treatment, azelastine is more better than olopatadine role more quickly, the effect is more pronounced.

作者秦礼宝李国梁

机构地区南京市浦口区中心医院

出处《中外医学研究》 2012年第26期17-18,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH

关键词变态反应性结膜炎盐酸奥洛他定盐酸氮卓斯汀 Allergic conjunctivitis Olopatadine Azelastine

分类号 R777.31 [医药卫生—眼科]

引文网络
相关文献

参考文献4

1Endre L.The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis[J].0rv Hetil, 2007, 148(6) : 251-254.
2陈建宏.0.1%盐酸奥洛他定滴眼液治疗季节性变态反应性结膜炎疗效观察[J].中国药物与临床,2010,10(11):1289-1291. 被引量：9
3韩冰,刘春民,王媛,陈静.两种药物治疗变态反应性结膜炎的疗效观察[J].国际眼科杂志,2012,12(1):114-115. 被引量：9
4张端晴,缪立昌.奥洛他定滴眼液治疗变态反应性结膜炎的临床观察[J].海峡药学,2009,21(3):88-89. 被引量：14

二级参考文献18

1Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0. 1% ophthalmic solution and loteprednol etabonate 0.2 % ophthalmic suspension in the conjuncrival allergen challenge model[J] . Clin Ther, 2002, 24(6):918-929.
2Berdy GJ,Hedqvist B.Ocular allergic disorders and dry eye disease:associations,diagnostic dilemmas,and management.Acta Ophthalmol Seand,2000,230(Suppl):32-37.
3Berdy GJ.The effects of systemic medication on ocular allergic disease.Acta Ophthalmologica,2000,78:26-31.
4Enerback L,Pipkom UG,Granerus G.Intraepithelial migration of nasal mucoal mast cells in hayfever.Int Arch:Allergy Appl Immunol,1986,80:44-51.
5Sharif N,Xu SX,Magnino P,et al.Human conjunctival cells express histaminel receptors coupled to phosphoinositide turnover and intracellular calcium mobilization:role in ocular allergic and inflammatory diseases.Exp Eye Res,1996,66:169-178.
6Abelson MS,Schaefer K.Conjunctivitis of allergicotigin:immunoiogic mechanisms and current approaches to therapy.Surv Ophthalmol,1993,38(Suppl):115-132.
7Jun J,Bielory L,Raizman MB.Vernal conjunctivitis,Immunol Allergy Clin North Am,2008,28(1):59-82.
8Berdy GJ,Hedqvist B.Ocular allergic disorders and dry eye disease:associations,diagnostic dilemmas,and management.Acta Ophthalmol Scand Suppl 2000;(230):32-37.
9James IG,Campbell LM,Harrison JM,et al.Comparison of the efficacy and tolerability of topically administered azelastine,sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhinoconjuncvitis.Curr Med Res Opin 2003;19(4):313-320.
10Endre L.The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis.Orv Hetil 2007;148(6):251-254.